The Common Drug Review (CDR) and Institut national d’excellence en santé et en services sociaux (INESSS) are currently welcoming patients to provide input to patient organizations on the manufacturer’s submission for upadacitinib (Rinvoq) for the treatment of ankylosing spondylitis (AS).Organizations supporting patients living with ankylosing spondylitis (AS) develop these patient input submissions whenever a drug of interest to people living with ankylosing spondylitis is under consideration. We would like to gather your views and share them with the CDR and INESSS. Your views will be anonymous and confidential.
Please use the following links to access the survey:
- English: https://www.surveymonkey.com/r/J3KF7GS
- French: https://www.surveymonkey.com/r/J3KF7GS?lang=fr_CA
The survey should take about 15 minutes to complete and will remain open until October 30, 2022.
Thank you for taking time to provide your input. By doing so you’re helping CSA and our partners advocate for a wide range of treatment options for those living with Spondyloarthritis.
Please contact us if you have any questions.